ORIC Pharmaceuticals Presents Enozertinib Data in NSCLC Patients with HER2 Exon 20 Mutations at the ESMO Asia Congress 2025
December 05, 2025 01:00 ET | Source: ORIC Pharmaceuticals Systemic activity of…
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
June 06, 2025 16:30 ET | Source: ORIC Pharmaceuticals SOUTH SAN FRANCISCO,…
